Our purpose was to evaluate the interobserver concordance
Our purpose was to evaluate the interobserver concordance for the diagnoses of mycosis fungoides (MF), atypical dermatoses (AD), and benign dermatoses (BD) and the impact of T-cell immunophenotyping on the diagnoses MF, AD, and BD. Specimens of MF (n = 57), AD (n = 27), and BD and normal skin (n = 54) were reviewed by 2 hematopathologists and 1 dermatopathologist to establish diagnostic interobserver concordance by routine morphologic examination. Immunophenotyping was performed to evaluate expression of CD2, CD3, CD4, CD5, CD7, CD8, CD20, CD30, and MIB-1. The interobserver concordance was fair to moderate compared with the original diagnosis. Partial deletion of CD2 alone was associated significantly with MF. Epidermal deletions of 2 or 3 T-cell antigens or 2 T-cell antigens not including CD7 were associated significantly with MF. An elevated CD4/CD8 ratio correlated with MF. Morphologic features were most diagnostic of MF. Immunophenotyping generally resulted in downgrading of the reaction pattern but was helpful in distinguishing MF from benign dermatoses.
Mycosis fungoides (MF) is the most common cutaneous lymphoma and accounts for nearly 50% of all primary cutaneous lymphomas. 1 MF often is difficult to distinguish from a number of benign inflammatory dermatoses clinically and histopathologically, [2] [3] [4] [5] [6] especially early in the course of the disease because morphologic features are not always diagnostic, and additional testing may be required for a definitive diagnosis of MF to be made. Pathologically, MF is a monoclonal tumor of epidermotropic T lymphocytes, usually of the CD4 helper phenotype. In early MF lesions, a band-like dermal infiltrate is composed of reactive and neoplastic T lymphocytes, the latter of which predominate in the epidermis. 7 As MF progresses from patch to plaque stages, the relative proportion of neoplastic T lymphocytes increases in the epidermis and dermis 7 so that histopathologic diagnosis is more straightforward in later stages of the disease. 6 Although routine morphologic features are the "gold standard" for the diagnosis of MF, ancillary studies, including T-cell immunophenotyping and T-cell receptor (TCR) gene rearrangement, may be performed on cases of suspected MF to provide additional evidence that "suspicious" histologic changes indeed may represent MF in the appropriate clinical setting. These testing modalities might help to more clearly identify a neoplastic T-cell proliferation by evidence of aberrant antigen expression patterns or a monoclonal TCR gene rearrangement.
We attempted to evaluate pathologic concordance in the morphologic diagnosis of MF by evaluation of a set of blinded skin biopsy specimens that included documented MF, suspicious lesions, inflammatory dermatoses, and normal skin. In addition, we evaluated the additional diagnostic information provided by immunohistochemical stains for T-cell antigens, proliferation, and activation in evaluation of T-cell lymphocyte infiltrates of the skin to see whether this additional testing modality would provide sufficient information to allow for a diagnosis of MF.
Materials and Methods
The present study met all requirements of and was approved by the University of Utah Health Sciences Center (Salt Lake City) Institutional Review Board (IRB 11074, approved November 27, 2002) .
Case Selection
Biopsy material from 3 subject groups was obtained during an interval from October 1990 to April 2003 from pathologic materials evaluated at the University of Utah Health Sciences Center. The first group included 57 skin biopsy specimens from 34 individuals with MF whose diagnosis was established by a combination of clinical manifestations, histologic features, and ancillary studies (including TCR gene rearrangement and T-cell marker profiling, when available). All subjects in this group had received treatment for MF, most in the setting of a multidisciplinary cutaneous lymphoma clinic. The number of specimens for each subject ranged from 1 to 4, and all had at least 1 specimen diagnosed as MF.
The second group included 27 skin biopsy specimens, from 18 individuals, that demonstrated morphologically atypical findings in the skin biopsy specimen but were without unequivocal histologic features of MF. These specimens had been diagnosed as "atypical lymphoid infiltrate" or "parapsoriasis" with a comment that MF could not be excluded. Despite the lack of a definitive histologic diagnosis of MF, the clinical criteria for MF were fulfilled in all cases, and patients had been or were undergoing treatment for it.
A control group included skin biopsy specimens from 54 individuals: normal skin obtained from the tips of excision specimens for unruptured epidermoid cysts, 9; lichenoid dermatitis, 13; spongiotic dermatitis, 12; pityriasis lichenoides et varioliformis acuta, 9; and psoriasis, 11.
Immunohistochemical Analysis
Formalin-fixed, paraffin-embedded tissue sections from each biopsy specimen were deparaffinized in xylene and absolute ethanol and then rehydrated by successive immersions in 95% ethanol, 70% ethanol, and distilled water. All immunoperoxidase staining was performed on a Ventana ES instrument (Ventana Medical Systems, Tucson, AZ) using the avidin-biotin-peroxidase complex according to manufacturer recommendations with appropriately staining negative and positive control samples. Primary antibodies to lymphocyte markers CD2, CD3, CD4, CD5, CD7, CD8, CD20, MIB-1, and CD30 were applied, and immunostaining was developed using diaminobenzidine (3,3'-diaminobenzidine). Slides were counterstained with hematoxylin. Dilutions and sources of the primary antibodies used in the study are given in ❚Table 1❚.
Evaluation of Slides
The H&E-stained sections were randomized with a random number generator (Excel, Microsoft, Redmond, WA). Before evaluation of the slides, diagnostic histologic criteria of MF were defined by the reviewers (2 hematopathologists, S.L.P. and M.C., and 1 dermatopathologist, S.R.F.). Morphologic diagnostic criteria for MF were based on those reported by Smoller et al 8 and were discussed as a group before review of the histologic slides. The criteria used as diagnostic for MF included the following:
1. Lymphocyte atypia, defined by nuclear enlargement (nucleus similar in size or larger than a neighboring keratinocyte nucleus), hyperchromasia, and irregular nuclear contours or cerebriform morphologic features 2. Epitheliotropism of lymphocytes (defined as having ingress of morphologically atypical lymphocytes, as described in No. 1, into the epithelium), including formation of Pautrier microabscesses (defined as a discreet cluster of at least 4 lymphocytes within the squamous epithelium) 3. Alignment of morphologically atypical lymphocytes along the epidermal side of the dermoepidermal junction 4. Expansion of the papillary dermis with coarsened collagen fibers that contain a dense infiltrate of morphologically atypical lymphocytes A definitive diagnosis of MF required at least 3 of the 4 morphologic criteria for MF to be present. Designation of a case as atypical included biopsy specimens that did not display sufficient diagnostic criteria for a diagnosis of MF but contained 1 or 2 of the preceding morphologic features. Designation as benign or normal skin required that none of the above morphologic criteria be present.
In the first phase of the study, the reviewers evaluated slides in random order, and a diagnosis was given by each independently according to the following categories: normal skin, benign dermatosis, atypical dermatosis, and MF. In phase 2, the H&E-stained slides were re-reviewed in random order and a diagnosis was given. In phase 3, the slides were organized into cases that included the routine H&E-stained profiles and corresponding immunohistochemical slides for each of the lymphoid markers. The 3 pathologists together reviewed the H&E-stained profiles without discussing their original assessment of the case. Each of the immunohistochemical markers was reviewed, and an estimation of the percentage of lymphoid cells stained was given separately for the epidermal and dermal inflammatory compartments, on a 10% scale (eg, 0%, 10%, 20%), similar to our clinical practices. The 3 pathologists agreed on the percentages. The CD4/CD8 ratio was calculated for the epidermal and dermal components of each specimen based on the estimated percentages. After reviewing all immunohistochemical markers, each of the reviewers gave a final diagnosis after interpreting the immunophenotypic profiles, but final diagnoses were not discussed. For phase 1 and phase 3 final diagnoses, an overall diagnosis for the 3 pathologists was established by agreement of 2 of 3 pathologists.
Data Analysis
All statistical analyses were performed using Statistica (StatSoft, Tulsa, OK) or StatXact-5 (Cytel Software, Cambridge, MA). Statistical significance of agreement with overall diagnosis was assessed by using the Fisher exact test.
Results of interobserver and intraobserver concordance were reported using the κ statistic, 9 a measure of the proportion of agreement between observers after chance agreement has been excluded. 9, 10 Values of κ may range from -∞ to 1, with negative κ indicating less agreement than would be expected by chance, 0 indicating exactly the amount of agreement expected by chance, and 1 indicating perfect agreement. 11 
Results

Subjects
The MF group comprised 34 individuals (26 men and 8 women) with an average age at the initial biopsy of 62.3 years (range, 26.9-85.9 years; median, 67.5 years). The "atypical" group comprised 18 individuals (12 men and 6 women) with an average age at the initial biopsy of 62.3 years (range, 20.2-88.8 years; median, 66.4 years).
Interobserver and Intraobserver Correlation
All slides were reviewed by 2 hematopathologists and 1 dermatopathologist experienced in diagnosis of cutaneous lymphomas. The pathologists each reviewed H&E-stained profiles of 138 cases and agreed with the original diagnosis for 91% of the benign dermatoses, 50% of the atypical dermatoses, and 36% of MF cases. When the original diagnoses of atypical dermatosis and MF were considered as a single diagnostic category, the raw agreement increased to 67%. Interobserver agreement with the original diagnosis was fair to moderate (κ range, 0.33-0.44). Phase 2 (intraobserver) agreement was moderate to good for all pathologists (κ range, 0.53-0.69). These data are summarized in ❚Figure 1❚.
T-Cell Antigen Deletion
T-cell antigens evaluated included CD2, CD3, CD5, and CD7. These markers were reviewed as a group for each case in phase 3 of the study. An antigen was considered partially deleted when an estimated 30% or more of the T-cell population was negative for that marker. Partial deletion of CD2 in both the epidermal and dermal compartments was associated significantly with a diagnosis of MF (P = .005 for the epidermis; P = .01 for the dermis). Epidermal or dermal deletion of CD3, CD5, or CD7 was not associated significantly with a final diagnosis of MF. In fact, CD7 was nonspecific, with partial deletion of this antigen seen in the majority of benign, atypical, and MF diagnoses, despite expected staining levels seen in the control slides ❚Table 2❚. When multiple antigens were deleted, only epidermal deletions of 2 or 3 T-cell antigens were associated significantly with a final diagnosis of MF (P < .001 for 2 epidermal deletions; P = .02 for 3 epidermal deletions). Deletions in T-cell antigens of the dermal component alone were not significant predictors of a final diagnosis of MF (P > .05).
CD4/CD8 Ratio
CD4 is not specific to T-helper cells and is expressed on Langerhans cells that also populate the epidermis and dermis, which can falsely elevate the estimated CD4/CD8 ratio, especially in specimens with prominent spongiotic changes of the epidermis. We found that estimation of this ratio was best ) or as number/total tested (percentage). † The CD2 was not interpretable or did not work after repeating for 1 specimen each designated atypical, MF, or normal skin; the CD7 was not interpretable or did not work after repeating for 1 specimen each designated atypical, spongiotic, or normal skin; as such, the denominator is reduced by 1. ‡ CD2 deletion was significantly associated with MF compared with other diagnostic possibilities: epidermal CD2 deletion, P = .005; dermal CD2 deletion, P = .01. § Loss of expression of CD3, CD5, or CD7 alone was not associated significantly with MF (P > .05) vs other diagnostic possibilities. || Deletion of 2 T-cell antigens in the epidermis was significantly increased in MF (P < .001).
¶ Including cases reclassified as benign at the final diagnosis.
accomplished by careful comparison of the epidermal and dermal CD8 compartments with pan-T-cell antigens, such as CD2, CD3, and CD5, to determine the approximate percentage of the T-cell population staining with CD8. The CD4 was then correlated with the CD8 and pan-T-cell antigens, and a final ratio was assigned to the epidermal and dermal compartments. We found that higher ratios were associated with an atypical or MF diagnosis but that the ratio was not a sensitive predictor of MF. The epidermal CD4/CD8 ratio averaged 3.5 for a final diagnosis of MF vs 1.6 for atypical cases and approximately 1.0 for benign diagnoses ❚Figure 2❚. For MF, the sensitivity and specificity of the epidermal CD4/CD8 ratio at 1:1 were 79% and 69%, respectively; at 2.4:1, 69% and 93%, respectively; and at 9:1, 24% and 98%, respectively ❚Figure 3❚. As such, elevated CD4/CD8 ratios are rather insensitive for separation of atypical and diagnostic cases, although when high (≥ 9:1) are specific for a diagnosis of MF. The dermal CD4/CD8 ratio averaged 2.2 for a final diagnosis of MF vs 1.6 for atypical cases and Anatomic Pathology / ORIGINAL ARTICLE 
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❚Figure 3❚ Sensitivity and specificity of the epidermal (A) and dermal (B) CD4/CD8 ratio for a diagnosis of mycosis fungoides. At an epidermal ratio of 2.4:1, the sensitivity was 69% and the specificity, 93%. At high ratios, specificity is maximized, whereas sensitivity is minimized. approximately 1.0 for benign diagnoses and was much less helpful for distinguishing between these diagnostic entities.
CD30 and MIB-1 Immunostaining
We also evaluated the expression of the activation antigen CD30 and proliferation antigen MIB-1 in the 138 specimens to determine whether these additional immunohistochemical markers could be used to help differentiate benign or malignant skin lesions. Generally speaking, patients given a final definitive diagnosis of MF had somewhat higher expression levels of CD30 in both the epidermis and dermis than found in benign skin diseases ❚Figure 4❚. The average expression of CD30 in MF cases was 14.6% and 14.8% in epidermis and dermis, respectively, compared with average expression levels of 4.3% and 7.8%, respectively, in benign skin cases. However, this difference was even less significant when atypical skin lesions were compared with benign skin lesions. In addition, the range of expression of CD30 was quite variable in MF cases (0%-80%) and benign skin diseases (0%-60%), making it impractical to use CD30 expression to differentiate benign and malignant skin diseases on a case-by-case basis.
MIB-1 (Ki-67) proliferation estimations showed findings similar to those for CD30. Overall, cases given a definitive diagnosis of MF demonstrated higher MIB-1 expression than seen in benign skin lesions. The average expression levels in MF cases were 11.0% and 21.4% in the epidermis and dermis, respectively, compared with 7.1% and 12.0% in benign skin cases. Cases categorized as atypical lymphoid infiltrates had generally low MIB-1 expression and were indistinguishable from the other benign dermatoses. As was seen with CD30, MIB-1 expression in MF also was quite variable, with a range of 0% to 60% of cells staining, and showed considerable overlap with benign dermatoses (range, 0%-50%). High MIB-1 scores were seen in the 3 cases of plaque-stage MF examined (average, 36.7% for the epidermis and 53.3% for the dermis) and in the 2 cases of CD8+ MF (average, 45% in the epidermis and dermis).
TCR Gene Rearrangement
Sixteen specimens were submitted, at the time of original diagnosis, for TCR gene rearrangement by reverse transcriptase-polymerase chain reaction methodology. The results were not available to the pathologists during examination of the H&E-stained and immunostained sections. A monoclonal or oligoclonal banding pattern was shown in 8 specimens, and 8 specimens were polyclonal. There was no significant association of monoclonality and a final diagnosis of MF in this small number of cases. Results are summarized in ❚Table 3❚.
Immunoprofiling Resulted in Downgrading of the Final Diagnosis
We were interested in evaluating the effect of T-cell immunoprofiling on the final (phase 3) diagnosis and how the final diagnosis incorporating information from the T-cell immunoprofiling compared with the initial (phase 1) diagnosis in which only the H&E-stained profiles were examined.
Final Diagnosis (Phase 3) vs Phase 1 Diagnosis
Overall, when the final diagnosis was compared with the initial (phase 1) impression on H&E-stained profiles, the final diagnosis matched the initial diagnosis in 65% of the cases. The diagnosis was upgraded in 12% of the cases: atypical to MF in 4 cases (5%), benign to atypical in 5 cases (6%), and benign to MF in 1 case (1%). Surprisingly, 23% of the cases were downgraded: MF to atypical in 5 cases (6%), MF to benign in 1 case (1%), and atypical to benign in 13 cases (15%).
Final Diagnosis (Phase 3) vs Original Diagnosis (Pathology Report)
When the final diagnosis was compared with the original diagnosis given at the time of the skin biopsy, there was agreement in only 40% of the cases. The diagnosis was upgraded in 5% of the cases: atypical to MF in 4 cases (5%).
The diagnosis was downgraded in 55% of the cases: MF to atypical in 17 cases (20%), MF to benign in 19 cases (23%), and atypical to benign in 10 cases (12%).
These data, summarized in ❚Table 4❚, suggest that the additional information provided by T-cell immunoprofiling, in most cases, results in no diagnostic change or downgrading of the reaction pattern.
Discussion
The objectives of the present study were to determine interobserver and intraobserver morphologic diagnostic concordance for a group of cases including a random distribution of benign processes, atypical dermatoses, and mycosis fungoides; validate the CD4/CD8 ratio in the epidermal and dermal compartments for MF compared with a control group of benign dermatoses and normal skin; and determine the effect of T-cell immunoprofiling on the final diagnosis of cutaneous lymphoid infiltrates, particularly in atypical cases that are not diagnostic of MF by morphologic examination. The diagnosis of MF is challenging because it often resembles clinically and histopathologically any of the multiple benign conditions so that the correct diagnosis may be delayed for years, even when multiple biopsy specimens have been obtained. 4 Not surprisingly, despite our review of published histologic criteria for the diagnosis of MF, the correlation between pathologists in this study was only fair to moderate, similar to other MF histopathologic correlation studies. 13, 14 Because of the difficulty in the histopathologic diagnosis of MF owing to overlap of features with benign conditions, ancillary studies such as T-cell immunophenotyping and TCR gene rearrangement often are applied to problematic cases to more clearly identify T-cell monoclonality and, in the correct clinical scenario, establish a diagnosis of MF.
MF tumor cells are typically of the CD4 T-helper phenotype. 15 Lack of expression of pan-T-cell antigens such as CD7 gained notoriety as a specific indicator of cutaneous T-cell lymphomas, [16] [17] [18] although subsequent reports have shown that CD7-T cells are common to benign and neoplastic T-cell infiltrates. 19 Indeed, we found that the majority of our cases, including benign control samples and normal skin, showed infiltrates of CD7-T cells. Partial deletion of CD2 in the epidermal or dermal inflammatory compartments was a specific finding associated with MF in a small number of cases, and a diagnosis of MF was more likely when multiple T-cell antigens were deleted. However, a recent study showed that loss of 2 or more pan-T-cell markers did not discriminate benign dermatoses from MF. 20 Clonal expansion of CD4 T cells resulting in elevation of the CD4/CD8 ratio has been reported to be of diagnostic value in MF. Nuckols and colleagues 21 reported that 15 of 23 MF cases had epidermal CD4/CD8 ratios of 2 or more and none had ratios less than 0.5. Izban and colleagues 22 reported substantially higher CD4/CD8 ratios among 35 MF cases, with 30 specimens having a CD4/CD8 ratio of at least 4:1 and 11 cases with a ratio of at least 10:1. Although the available data suggest that the CD4/CD8 ratio is elevated in MF, an appropriate cutoff value is controversial and seems to be dependent, in part, on the personal experience of the pathologist signing out the case. Because CD4 is expressed on Langerhans cells, we found that estimation of the CD4/CD8 ratio was best accomplished by comparison of epidermal and dermal CD8 compartments with pan-T-cell antigens to determine the approximate proportion labeling with CD8. A similar strategy uses a CD8/CD3 ratio. 23 We found that the epidermal CD4/CD8 ratio among cases with a final diagnosis of MF was 3.5, but this average ratio included 4 biopsy specimens from CD8 MF cases. When only CD4 MF cases were considered, all had a CD4/CD8 ratio of at least 2.4. Although there was some overlap with the atypical cases (Figure 2) , none of the benign dermatoses had CD4/CD8 ratios of more than 1.5:1. The CD4/CD8 ratio for the dermal compartment was more variable, although the findings were similar. As such, it seems that a cutoff value of at least 2.4:1 in the epidermal compartment maximizes sensitivity (69%) and specificity (93%).
Because of the great variability seen in MIB-1 and CD30 expression, these immunologic studies are not generally useful in distinguishing early MF from benign chronic dermatoses. High MIB-1 expression was seen in cases of plaque-stage MF and in CD8+ subtypes of MF. These findings are expected in these clinically more advanced or aggressive cases.
Identification of a rearrangement of TCR genes in a clonally expanded subset of cells infiltrating the skin is used in the clinical setting to confirm the diagnosis of MF. 16, 24 This test, however, lacks sensitivity because a TCR gene rearrangement is identified in only 50% to 69% of cases of patch-stage MF 16, [25] [26] [27] ; specificity also is problematic because clonally rearranged lymphoid populations are identified in clinically benign dermatoses and other nonneoplastic lymphoid tissue samples [28] [29] [30] [31] [32] ; thus, monoclonality is not synonymous with malignancy. As such, it was not surprising that results of TCR gene rearrangement in 16 subjects were not predictive of the final diagnosis. Interpretation of these data is difficult because many of the tested specimens had inconclusive histopathologic features, and TCR gene rearrangement was done in an attempt to more specifically categorize a biopsy specimen.
We were not surprised to find that the additional information provided by T-cell immunophenotyping most often resulted in no change in diagnosis or downgrading of the reaction pattern. In other words, when histopathologic features raised the possibility of MF but were insufficient for an unequivocal diagnosis, immunophenotyping generally did not help establish a more definitive diagnosis. MF is one of the most difficult diagnostic problems in dermatopathology 6, 13, 23, [33] [34] [35] and has resulted in a number of histologic algorithms and grading schemes 20, 36, 37 conveying to the clinician the degree of certainty with which the diagnosis was made.
As with most diseases that demonstrate a spectrum of clinical and pathologic findings, cases that are not MF and those that are classic MF are properly recognized without difficulty. However, many cases tend to fall somewhere between the 2 extremes, in the indeterminate category. At our institution, patients with chronic dermatoses that are suspicious for MF are referred for evaluation in a multidisciplinary lymphoma clinic to allow for optimal correlation of clinical and morphologic features and ancillary testing. Dermatologists, medical and radiation oncologists, hematopathologists, and dermatopathologists involved in this clinic are acutely aware of the challenge of diagnosis of cutaneous lymphomas, especially MF. Use of a weighted point system for diagnosis of MF incorporates clinical features such as lesion distribution and morphologic features, routine histopathologic findings, and ancillary studies, including T-cell immunophenotyping and TCR gene rearrangement by polymerase chain reaction ❚Table 5❚, belying the importance of arriving at a diagnosis of MF only after assimilation of clinical and histologic features and ancillary studies. Indeed, Stevens and colleagues 20 recently described their 7-year experience with this type of integrative approach to diagnosis.
Several limitations of this study warrant discussion. Each of the individuals with MF or atypical biopsy specimens had been diagnosed with MF in the setting of a multidisciplinary lymphoma clinic. Because this patient population is skewed by referral of individuals with chronic, often recalcitrant dermatoses suspicious for MF, it is possible that some of them may have been given an incorrect diagnosis. Identification of such individuals is problematic because the natural history of their disease is altered by therapy; consequently, the impact on our data set is difficult to assess. Contamination of the atypical group by skin biopsy specimens from individuals with and without MF mimics clinical practice and was the impetus for determining whether atypical but nondiagnostic specimens could be better classified by the use of a panel of immunohistochemical markers for Tcell antigens, thereby increasing our diagnostic sensitivity for early stages of disease. This was not found to be the case. We conclude from our results that immunoprofiling added little additional information in diagnostically challenging specimens. Likewise, Piepkorn and others 38 studied T-cell subsets in cases of MF and Sézary syndrome and came to a similar conclusion. We found, as expected, that results of the atypical group in general were intermediate between MF and benign dermatoses.
We chose a semiquantitative, gestalt method for estimating the percentage of lymphocytes marking with T-cell antigens because this more accurately reflects clinical practice. Although estimation is straightforward at the extremes (ie, 0% and 100% of lymphocytes labeling), it is more arbitrary centrally.
The results of this study demonstrate that the gold standard for histologic diagnosis of MF remains routine histopathologic examination. In our hands, the additional information provided by a battery of immunohistochemical stains was only supportive of a diagnosis of MF when the histologic features alone were consistent with MF. Indeed, immunohistochemical stains were of limited usefulness for establishing a specific diagnosis in difficult cases in which the routine pathologic features were atypical but insufficient for MF. In this setting, immunoprofiling, more often than not, resulted in downgrading the level of atypicality.
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